10x Genomics, Inc.

NasdaqGS:TXG Rapport sur les actions

Capitalisation boursière : US$2.7b

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

10x Genomics Gestion

Gestion contrôle des critères 4/4

Le PDG 10x Genomics' est Serge Saxonov, nommé en Jul2012, a un mandat de 12.08 ans. La rémunération annuelle totale est $ 8.29M, composée du salaire de 6.6% et des bonus 93.4%, y compris les actions et options de la société. détient directement 3.34% des actions de la société, d'une valeur de $ 90.59M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 6.5 ans et 5.3 ans.

Informations clés

Serge Saxonov

Directeur général

US$8.3m

Rémunération totale

Pourcentage du salaire du PDG6.6%
Durée du mandat du directeur général12.1yrs
Propriété du PDG3.3%
Durée moyenne d'occupation des postes de direction6.5yrs
Durée moyenne du mandat des membres du conseil d'administration5.3yrs

Mises à jour récentes de la gestion

Recent updates

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

Jun 14
Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

May 21
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Apr 15
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

10x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum

Oct 12

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Oct 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Analyse de la rémunération des PDG

Comment la rémunération de Serge Saxonov a-t-elle évolué par rapport aux bénéfices de 10x Genomics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$240m

Mar 31 2024n/an/a

-US$264m

Dec 31 2023US$8mUS$545k

-US$255m

Sep 30 2023n/an/a

-US$223m

Jun 30 2023n/an/a

-US$172m

Mar 31 2023n/an/a

-US$174m

Dec 31 2022US$19mUS$504k

-US$166m

Sep 30 2022n/an/a

-US$167m

Jun 30 2022n/an/a

-US$142m

Mar 31 2022n/an/a

-US$89m

Dec 31 2021US$12mUS$430k

-US$58m

Sep 30 2021n/an/a

-US$455m

Jun 30 2021n/an/a

-US$504m

Mar 31 2021n/an/a

-US$533m

Dec 31 2020US$11mUS$400k

-US$543m

Sep 30 2020n/an/a

-US$134m

Jun 30 2020n/an/a

-US$78m

Mar 31 2020n/an/a

-US$49m

Dec 31 2019US$2mUS$394k

-US$31m

Sep 30 2019n/an/a

-US$100m

Jun 30 2019n/an/a

-US$105m

Mar 31 2019n/an/a

-US$105m

Dec 31 2018US$1mUS$366k

-US$112m

Rémunération vs marché: La rémunération totale de Serge ($USD 8.29M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 6.74M ).

Rémunération et revenus: La rémunération de Serge a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Serge Saxonov (47 yo)

12.1yrs

Titularisation

US$8,286,050

Compensation

Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Serge Saxonov
Co-Founder12.1yrsUS$8.29m3.34%
$ 90.7m
Benjamin Hindson
Co-Founder12.1yrsUS$4.43m2.68%
$ 72.8m
Justin McAnear
Chief Financial Officer5.8yrsUS$3.31m0.046%
$ 1.3m
Eric Whitaker
Chief Legal Officer7.1yrsUS$3.88m0.12%
$ 3.2m
Michael Schnall-Levin
Founding Scientist & CTO2.6yrspas de donnéespas de données
Cassie Corneau
Manager of Investor Relations and Strategic Financeno datapas de donnéespas de données
Rebecca Port
Chief People Officer3.6yrspas de donnéespas de données
Jens Durruthy
Associate Director of Product Managementno datapas de donnéespas de données

6.5yrs

Durée moyenne de l'emploi

48.5yo

Âge moyen

Gestion expérimentée: L'équipe de direction de TXG est chevronnée et expérimentée (ancienneté moyenne 6.5 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Serge Saxonov
Co-Founder12.1yrsUS$8.29m3.34%
$ 90.7m
Benjamin Hindson
Co-Founder12.1yrsUS$4.43m2.68%
$ 72.8m
Kimberly Popovits
Independent Director4.4yrsUS$338.71k0.0038%
$ 104.2k
John Stuelpnagel
Independent Chairman11yrsUS$403.59k2.03%
$ 55.1m
Shehnaaz Suliman
Independent Director5yrsUS$336.39k0.0038%
$ 104.2k
Alan Mateo
Directorless than a yearpas de donnéespas de données
Mathai Mammen
Independent Director7yrsUS$331.39k0.14%
$ 3.9m
Sridhar Kosaraju
Independent Director5.3yrsUS$346.39k0.029%
$ 800.1k
Sarah Polonius-Teichmann
Directorless than a yearpas de donnéespas de données

5.3yrs

Durée moyenne de l'emploi

54.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de TXG sont considérés comme expérimentés (ancienneté moyenne 5.3 ans).